Abera Bioscience

Abera Bioscience Debt

Debt of Abera Bioscience (ABERA.SL) as of Oct 19, 2026.

Debt

0.00SEK

Last updated:

In 2021, Abera Bioscience's total debt was 0.00 SEK, a % change from the 0.00 SEK total debt recorded in the previous year.

The Abera Bioscience Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
0.00 SEK
Jan 1, 2018
0.00 SEK
Jan 1, 2019
0.00 SEK
Jan 1, 2020
0.00 SEK
Jan 1, 2021
0.00 SEK
The Abera Bioscience Debt history
YEARDebtYoY
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Abera Bioscience Stock analysis

What does Abera Bioscience do? Abera Bioscience AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company focuses on the research and development of pharmaceutical products, particularly in the field of vaccine development. It utilizes a proprietary vaccine delivery platform to advance vaccine candidates toward late pre-clinical or early clinical stages. Abera Bioscience aims to identify licensing partners for further development of its vaccine candidates. The company's technology is primarily applied in the development of vaccines targeting pneumococci and immunooncology. Abera Bioscience has a small operational footprint, employing five full-time staff members. It completed its initial public offering (IPO) on February 24, 2021, and is listed under the ticker ABERA.SL with ISIN SE0015245097. The company's headquarters are located in Uppsala, and it operates primarily within the Nordic market. Its website is https://aberabio.com/. The company's activities are centered on advancing vaccine candidates through its platform technology, with an emphasis on strategic partnerships for subsequent development phases. Abera Bioscience is one of the most popular companies on Eulerpool.

Debt Details

Understanding Abera Bioscience's Debt Structure

Abera Bioscience's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Abera Bioscience's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Abera Bioscience’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Abera Bioscience’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Abera Bioscience stock

On Eulerpool you can find the complete historical development of Debt Abera Bioscience since 2006 – with annual values, charts, and detailed analysis.

Debt's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Abera Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Abera Bioscience

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Abera Bioscience